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Abstract: The actions of tumor promoters on the coupling 
of muscarinic receptors to the hydrolysis of inositol lipids 
and the generation of Ca2+ signals were examined in the hu- 
man neuroblastoma SH-SY5Y cell line. Pretreatment of SH- 
SY5Y cells with 50 nM 12-0-tetradecanoylphorbol 13-acetate 
(TPA) for 5 days resulted in neuronal differentiation, a 28% 
decrease in both N-[3H]methylscopolamine and [3H]- 
scopolamine binding, and a significantly larger reduction 
(48%) in agonist-stimulated 3H-inositol phosphate generation. 
Whereas mezerein could mimic the effects produced by TPA, 
the biologically inactive 4a-phorbol 12,13-didecanoate was 
without effect on both antagonist binding and agonist-stim- 
ulated phosphoinositide (PPI) turnover. A decline (- 50%) 
in the agonist-mediated rise in cytoplasmic Ca2+ and a sub- 
stantial loss of protein kinase C activity also were observed 
following pretreatment with TPA or mezerein. The ability 
of fluoride, an agent capable of direct activation of guanine 
nucleotide binding proteins, to stimulate 3FI-inositol phos- 
phate release was significantly reduced in SH-SYSY cells 
treated with these agents. Furthermore, pretreatment of SH- 
SYSY neuroblastoma cells with TPA or mezerein impaired 
3H-inositol phosphate formation induced by the addition of 
either guanosine 5’-0-( 3-thiotriphosphate) or carbamylcho- 
line to digitonin-permeabilized cells, but not that elicited by 
the addition of 2 mM CaC12. Although cells cultured in the 
presence of serum-free media also exhibited neuronal differ- 
entiation, no significant alteration in either muscarinic re- 
ceptor number or agonist-stimulated PPI hydrolysis was ob- 
served. The results suggest that TPA and mezerein decrease 
agonist-stimulated PPI hydrolysis and Ca2’ signaling in SH- 
SYSY cells not only by a reduction in muscarinic receptor 
number but also through an inhibition ofguanine nucleotide- 
stimulated PPI turnover. Key Words: Phosphoinositidc- 
Human neuroblastoma-SH-SYSY-Muscarinic receptor- 
Mezerein- 12-0-Tetradecanoylphorbol 13-acetate. Cioffi 
C.  L. and Fisher S. K. Reduction of muscarinic receptor 
density and of guanine nucleotide-stimulated phosphoino- 
sitide hydrolysis in human SH-SY5Y neuroblastoma cells 
following long-term treatment with 12-0-tetradecanoyl- 
phorbol 13-acetate or mezerein. J.  Neurochem. 54, 1725- 
I734 (1990). 
Human neural tumor cells, such as the SH-SY5Y 
neuroblastorna clone, can differentiate morphologically 
upon prolonged exposure to low concentrations of the 
biologically active phorbol ester, I 2-0-tetradecanoyl- 
phorbol 13-acetate (TPA), an activator of protein ki- 
nase C (PKC) (Akerman et al., 1984; Nishizuka, 1984; 
Adem et al., 1987; Heikkila et al., 1987). This neuronal 
differentiation is associated with neurite outgrowth 
(Pahlman et al., 198 1, 1984), electrical excitability 
(Akerman et al., 1984), increases in neurotransmitter 
levels, and neurosecretory granules (Pahlman et al., 
198 1). Although the effects of phorbol esters on difler- 
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entiation have been well documented, little is known 
of possible alterations in signal transduction mecha- 
nisms under these conditions. SH-SYSY neuroblas- 
toma cells express muscarinic acetylcholine receptors 
(Adem et al., 1987; Serra et al., 1988; Lambert et al., 
1989), which are coupled to breakdown of inositol lip- 
ids (Serra et al., 1988; Fowler et al., 1989). Previous 
reports have demonstrated that chronic TPA treatment 
induces a down-regulation of muscarinic receptor 
number in this neuronal clone (Adem et al., 1987; 
Heikkila et al., 1987). In the present study, we have 
utilized SH-SYSY cells to examine the coupling of 
muscarinic receptors to the hydrolysis of inositol lipids 
and Ca2+ signaling following differentiation by means 
of either TPA or mezerein, or, alternatively, by depri- 
vation of fetal calf serum. The results indicate that 
whereas long-term treatment of SH-SYSY cells with 
either TPA or mezerein elicits a reduction in musca- 
rink receptor number, an even more pronounced in- 
hibition of agonist-stimulated inositol phosphate gen- 
eration and of Ca2+ mobilization occurs. Furthermore, 
using either intact cells stimulated with fluoride or dig- 
itonin-permeabilized cells stimulated with guanosine 
5'-0-(3-thiotriphosphate) (GTPyS), we demonstrate 
that the effects of TPA and mezerein on inositol lipid 
turnover result not only from a loss of muscarinic re- 
ceptors, but also from an inhibition of the guanine nu- 
cleotide binding protein (G,) that regulates phospho- 
inositide (PPI) hydrolysis in these cells. In contrast with 
the effects observed for tumor promoters, no significant 
changes in either muscarinic receptor density or ago- 
nist-stimulated PPI hydrolysis occurred when differ- 
entiation was induced by culturing SH-SYSY cells in 
serum-free media. 
MATERIALS AND METHODS 
my0-[2-~H]Inositol (15 Ci/mmol) was obtained from 
American Radiolabeled Chemicals (St. Louis, MO, U.S.A.). 
[y3'P]ATP (5,000 Ci/mmol) was purchased from Amersham 
Corporation (Chicago, IL, U.S.A.). N-[3H]Methylscopol- 
amine ([3H]NMS; 73.8 Ci/mmol) and Lpr0py/-2,3-~H]- 
benzilylcholine mustard ( [3H]PBCM; 52 Ci/mmol) were 
from New England Nuclear (Boston, MA, U.S.A.). [3H]- 
Scopolamine (75 Ci/mmol) was custom synthesized by 
Amersham Corp. Dowex AG I-X8 (100-200 mesh, formate 
form) and Bio-Rad Protein Assay were obtained from Bio- 
Rad Labs (Rockville Center, NY, U.S.A.). Pirenzepinc 
was obtained from Boehringer-Ingelheim (Ridgefield, CT, 
U.S.A.). GTP-yS was purchased from Boehringer-Mannheim 
(Indianapolis, IN, U.S.A.). Carbamylcholine, digitonin, 
HEPES, mezerein, 4a-phorbol 12,13-didecanoate (4a-PDD), 
TPA, phenylmethylsulfonyl fluoride, dithiothreitol, histone 
111-S, phosphatidylserine, Triton X- 100, 1,2-diolein, and leu- 
peptin were obtained from Sigma Chemical Co. (St. Louis, 
MO, U.S.A.). Diethylaminoethyl (DEAE)-Sephacel was from 
Pharmacia Biotechnology (Gaithersburg, MD, U.S.A.). Tissue 
culture supplies were obtained from Corning Glass Works 
(Corning, NY, U.S.A.). Powdered Dulbecco's modified Ea- 
gle's medium (DMEM) and fetal bovine serum (FBS) were 
purchased from Grand Island Biological Co. (Grand Island, 
NY, U.S.A.). The SH-SY5Y cell line was kindly provided by 
Dr. June L. Biedler of the Sloan-Kettering Institute for Can- 
cer Research (Rye, NY, U.S.A.). 
Cell culture conditions 
Human SH-SY5Y neuroblastoma cells (passage 65-80) 
were grown in tissue culture flasks (75 cm2/250 ml) in 20 ml 
of DMEM with high glucose supplemented with 10% (vol/ 
vol) FBS. The cells were incubated at 37°C in an atmosphere 
consisting of 10% COz and 90% humidified air. Confluent 
cells grown for 10-20 days were subcultured by incubation 
in a modified Puck's D, solution (Honegger and Richelson, 
1976). The cells were collected by centrifugation (300 g for 
1 min), resuspended into DMEM, and redistributed into cul- 
ture flasks. The culture medium was changed on day 5 and 
on alternate days thereafter by the addition of 10 nil of fresh 
DMEM and removal of 10 ml of medium. 
Differentiation 
Confluent cells were subcultured in tissue culture flasks 
(75 cm2/250 ml) in DMEM with 10% FBS in the absence or 
presence of TPA (50 M) or mezerein (100 nM). Stock so- 
lutions were prepared in absolute ethanol and were always 
introduced to newly passaged cells; the same ethanol con- 
centration was present in the control cells. All experiments 
were performed with 80-90% confluent cultures on day 5 
following subculture. For differentiation in the absence of 
fetal calf serum, cells were grown in the presence of DMEM 
alone for 6-7 days. Intact cells were harvested for assay as 
described above. The cell pellet was resuspendcd in HEPES 
physiological salt buffer solution (142 mM NaCI, 5.6 mM 
KCI, 2.2 mM CaCI2, 3.6 mA4 NaHC03, 1 mM MgC12, 5.6 
m M  D-glucose, and 30 mM Na' HEPES; pH 7.4). 
Electrophoresis of labeled muscarinic receptors 
Intact SH-SY5Y cells were labeled with [3H]PBCM, ana- 
lyzed by sodium dodecyl sulfate-urea gel electrophoresis and 
visualized autoradiographically as described previously 
(Fisher and Heacock, 1988). 
Radioligand binding assays 
The binding of [3H]NMS and [3H]scopolamine to mus- 
carinic receptors on intact SH-SY 5Y cells was measured as 
previously described (Fisher, 1988). 
Assay for release of labeled inositol phosphates 
Intact cells. SH-SYSY cells were harvested as described 
above, resuspended in HEPES buffer containing [3H]inositol 
(- 10 gCi/ml) at a protein concentration of 1 mg/ml, and 
allowed to prelabel for 60 min at 37°C. After 55 min, lithium 
chloride was added to achieve a final concentration of 10 
mM. The reaction was initiated by the addition of 50 p1 of 
carbamylcholine or buffer to assay tubes containing 45O-pl 
aliquots of labeled cells followed by a 60-min incubation at 
37°C. When fluoride was used as an activator, intact cells 
were allowed to prelabel overnight with 5 pCi/ml [3H]inositol. 
A 50-pl aliquot of NaF was added to assay tubes containing 
450 p1 of labeled cells and incubated for 20 min at 37°C. (A 
20-min incubation was chosen due to the lack of linearity of 
NaF-stimulated 3H-inositol phosphate formation with fur- 
ther incubation.) The reaction was terminated by addition 
of 1.5 ml of chloroform/methanol(1:2, vol/vol), and the total 
water soluble inositol phosphate fraction was scparated and 
quantitated by ion-exchange chromatography (Fisher and 
Snider, 1987). The majority of the radiolabel recovered was 
in inositol monophosphate (63%), with the remainder in 
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glycerophosphorylinositol (34%), inositol bisphosphate 
(2.3%), inositol trisphosphate (0.4%), and inositol tetrakis- 
phosphate (0.3%). The ratios of 3H-inositol phosphates re- 
mained unchanged following TPA treatment. Basal levels of 
3H-inositol phosphate release were subtracted from all car- 
bamylcholine- and NaF-stimulated values. In all experiments, 
a 200-p1 aliquot was removed from the organic phase to de- 
termine the incorporation of [3H]inositol into the phospho- 
lipid fraction (Fisher and Bartus, 1985). 
Permeabilized cells. The release of inositol phosphates from 
digitonin-permeabilized cells was measured as described pre- 
viously (Fisher et al., 1989). 
Measurement of cytoplasmic calcium concentration 
Cytoplasmic Ca” concentrations ([Ca*+]J were determined 
by the use of the fluorescent Ca2+ indicator, fura-2, as pre- 
viously described (Fisher et al., 1989). Single-wavelength flu- 
orescence was routinely monitored using a Shimadzu RF- 
5000 spectrofluorophotometer. In some experiments, [Ca2+Ii 
in fura-2/AM-loaded cells was determined by the dual-wave- 
length method of Grynkiewicz et al. (1985) by manual 
switching of the excitation wavelengths. Both methods yielded 
similar results. 
PKC assay 
Intact SH-SY5Y cells were harvested as described above 
and homogenized at 4°C in three volumes of homogenization 
buffer (20 mMTris-HC1, pH 7.5, I mMEGTA, 1 mMEDTA, 
2 mM dithiothreitol, 250 mM sucrose) plus 1 mM phenyl- 
methylsulfonyl fluoride, 50 pg/ml leupeptin, and 1 pg/ml 
pepstatin A using a Brinkmann Polytron (setting 7, three 5- 
s bursts). The homogenate was centrifuged at 100,000 g for 
60 min at 4°C. The resultant supernatant fluid was collected 
and is referred to as the cytosolic fraction. To solubilize any 
PKC activity tightly associated with the membrane, the 
membrane pellet was resuspended in Tris homogenization 
buffer containing 0.1% Triton X-100 and extracted on ice 
for 45 min. Following centrifugation at 100,000 g for 60 min 
at 4”C, the supernatant fluid was collected to obtain the 
membrane fraction. The resultant cytosolic and membrane 
fractions were loaded onto DEAE-Sephacel columns (I-ml 
bed volume) previously equilibrated with homogenization 
buffer. The columns were washed with five volumes of the 
same buffer, and PKC was eluted with 100 mM NaCl in 
homogenization buffer. PKC activity was determined by 
measuring the transfer of 32P from [y3’P]ATP to histone. 
The standard reaction mixture contained 20 mM Tris-HC1 
(pH 7 4 ,  5 mM magnesium acetate, 45 pM CaCl,, 200 pg 
histone III-S/ml, 250 pM [y-32P]ATP, 160 pg phosphatidyl- 
serine/ml, 1.6 pg diolein/ml, and the enzyme solution to be 
assayed in a final volume of 250 pl. Phosphatidylserine and 
diolein were dried from chloroform and sonicated in 20 mM 
Tris-HCI (pH 7.5). The reactions were performed in plastic 
tubes and were initiated by the addition of 30 and 50 pl of 
the cytosol and membrane fractions, respectively. After 5 
min at 3 0 T ,  the assay was terminated by the addition of 3 
ml of 25% trichloroacetic acid (TCA) and filtered over a Mil- 
lipore filter (0.45 pm). The tubes were washed three times 
with 25% TCA and the contents added to the filter; two further 
TCA washes of the filter followed. PKC activity was computed 
according to the following equation: 
PKC activity = A - (B  - C) 
where A = the amount of 32P incorporation into histone in 
the presence of tissue extract, Ca’+, phosphatidylserine, and 
diolein; B = the amount of 32P incorporation into histone in 
the presence of Ca2+ and tissue extract; and C = the amount 
of 32P incorporation into histone in the presence of 20 mM 
EGTA and tissue extract (no Ca”, phosphatidylserine, or 
diolein). 
Background activity was determined in samples in which 
tissue, phosphatidylserine, diolein, and Ca2+ were omitted 
and an additional 20 mM EG‘TA added. 
Data analysis 
Results are expressed as mean f SEM values. Student’s t 
tests (paired or unpaired) were used to determine statistical 
significance. Proteins were measured according to the method 
of Geiger and Bessman (1972), except for the PKC assay, 
where interference from assay reagents necessitated the use 
of Bio-Rad Protein Assay. Apparent Ki values for radioligand 
binding studies were calculated from the Cheng and Prusoff 
equation (1973). Competition curves were analyzed by the 
LIGAND program (Munson and Rodbard, 1980). Saturation 
isotherms were analyzed according to the Scatchard trans- 
formation ( 1949). 
RESIJLTS 
Characterization of muscarinic acetylcholine 
receptors on SH-SYSY cells 
Because some uncertainty exists regarding the phar- 
macological identity of the muscarink receptors pres- 
ent on SH-SYSY cells (Adem et al., 1987; Serra et al., 
1988; Lambert et al., 1989), our initial studies were 
directed toward a pharmacological and biochemical 
characterization of the receptor subtype expressed in 
the cell line used during the course of the present study. 
When [3H]NMS and [3H]scopolamine were utilized to 
characterize muscarinic receptors, both ligands labeled 
receptors on intact, confluent SH-SY5Y cells (- 12 
days in culture) in a specific and saturable manner 
yielding B,,, values of 352 k 38 and 397 k 2 fmol/ 
mg of protein (n = 3), respectively (Fig. 1); the average 
KD values were 0.82 f 0.23 and 0.95 +. 0.20 nM, re- 
spectively. The MI-selective antagonist pirenzepine was 
able to compete for all sites labeled by [3H]NMS (Fig. 
2). The K, value obtained for pirenzepine displacement 
was 700 k 100 &(n = 3), indicating the presence of 
a class of muscarinic receptors with low affinity for the 
antagonist, in agreement with the results of Lambert 
et al. (1989). Although the Hill coefficients (0.89 k 0.03; 
Fig. 2 )  were significantly less than 1.0 ( p  < 0.05), the 
data could only be successfully fit by LIGAND ac- 
cording to a one-site model. However, a small number 
of high-affinity pirenzepine binding sites has been de- 
tected in two previous reports using this clone (Adem 
et al., 1987; Serra et al., 1988). 
SH-SYSY cells are a subclone of the parent SK-N- 
SH neural cell line (Biedler et al., 1978), which has 
been found to exhibit an M3 muscarink subtype that 
couples to PPI turnover (Fisher and Heacock, 1988). 
To investigate whether SH-SYSY neuroblastoma cells 
express the same muscarinic receptor subtype as the 
parent cell line, intact SH-SY5Y cells were labeled With 
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FIG. 1. Scatchard analysis of the binding of [3H]NMS and 
[3H]scopolamine to muscarinic receptors on intact SH-SY5Y cells. 
SH-SY5Y cells (-400 pg of protein) were incubated with either 
0.2-5.0 nM [3H]NMS or 0.15-10.0 nM [3H]scopolamine for 120 
min at 37°C. Nonspecific binding was assessed in the presence 
of 50 pM atropine. Results shown are representative of three in- 
dependent experiments. 
[3H]PBCM and the labeled peptides analyzed by so- 
dium dodecyl sulfate-urea gel electrophoresis. A major 
labeled species of M, 98,000 was detected, as previously 
observed for the parent SK-N-SH cell line (Fig. 3; Fisher 
and Heacock, 1988). Taken together, these findings 
suggest that the SH-SY5Y cell line used in the present 
study contains a high density of high molecular weight 
muscarinic receptors of the M3 (pirenzepine low-affin- 
ity) subtype, and are in agreement with the pharma- 
cological data recently presented by Lambert et al. 
( I  989) for the same cell line. Furthermore, both the 
biochemical and pharmacological properties of the 
muscarinic receptors present on SH-SYSY neuroblas- 
toma cells appear to be very similar to those observed 
-Log Prenzepine, (MI 
FIG. 2. Competition for specific [3H]NMS binding sites by piren- 
zepine in SH-SY5Y cells. Intact cells were incubated for 120 min 
at 37°C with 5 nM [3H]NMS in the presence of increasing con- 
centrations of pirenzepine. The specific 13H]NMS binding in the 
absence of displacer was 21 9 fmol/mg of protein. Data shown are 
from three independent experiments with an average Hill coefficient 
value of 0.89 f 0.03 (significantly different from 1 .O; p < 0.05). 
However, in each experiment, the displacement data (up to 21 
points) were only successfully fit by LIGAND to a one-site model. 
FIG. 3. A high Mr muscarinic receptor is present in both SH-SY5Y 
and SK-N-SH neuroblastoma cells. Intact SH-SY5Y cells (lanes 1 
and 2) or SK-N-SH cells (lanes 3 and 4) were labeled with [3H]PBCM, 
and labeled peptides were then analyzed by sodium dcdecyl sulfate- 
urea gel electrophoresis. Samples in lanes 2 and 4 were incubated 
with 10 pl4 atropine prior to labeling with [3H]PBCM. The molecular 
weight markers, in order of decreasing M,, were myosin, P-galac- 
tosidase, phosphorylase b, bovine serum albumin, ovalbumin, and 
carbonic anhydrase. 
for the parent SK-N-SH cell line (Fisher and Heacock, 
1988). 
Changes in cell morphology of SH-SY5Y cells 
treated with either TPA or mezerein or cultured 
in the absence of fetal calf serum 
SH-SYSY cells, cultured for up to 5 days in the pres- 
ence of 50 nA4 TPA, expressed long, neuritic processes 
indicative of neuronal differentiation, as previously 
described (Pahlman et al., 1981, 1984; Adem et al., 
1987; Heikkila et al., 1987). Identical morphological 
changes were induced by treatment with 100 nA4 me- 
zerein. When SH-SYSY cells were cultured for up to 
7 days in media devoid of fetal calf serum, morpho- 
logically differentiated cells also resulted. Although 
these cells had long, straight processes, the appearance 
of many cell clusters and greater distances between cells 
made them morphologically distinct from cells treated 
with TPA or mezerein. 
Changes in muscarinic receptor density and 
3H-inositol phosphate generation following 
long-term TPA treatment 
Addition of 50 nM TPA to newly passaged cells for 
various times resulted in a gradual, time-dependent 
loss of both [3H]NMS and [3H]scopolamine binding 
sites to -70% of control values at 5 days (Fig. 4). Under 
similar conditions, there was also a time-dependent, 
albeit larger, inhibition of muscarinic receptor-stimu- 
lated accumulation of 3H-inositol phosphates (Fig. 4). 
Acute exposure of SH-SY5Y cells to 50 I&' TPA for 
either 15 min or 18 h had little or no effect on specific 
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FIG. 4. Time course of TPA-induced decrease in muscarinic re- 
ceptor density and of carbamylcholine-stimulated 3H-inositol phos- 
phate generation. SH-SY5Y cells were pretreated with 50 nM TPA 
for the designated times and harvested for assay as described in 
Materials and Methods. Binding to muscarinic receptors was de- 
termined by incubating intact cells with 5 nM [3H]NMS (0) or 8 nM 
[3H]scopolamine (0) in the presence or absence of 50 pM atropine 
for 120 min at 37OC. For the sake of clarity, one line has been 
drawn to designate the binding of both ligands to muscarinic re- 
ceptors. Total 3H-inositol phosphate release (.) was measured as 
described in Materials and Methods using 10 mM carbamylcholine. 
Data are expressed relative to control cells, which were not pre- 
treated with TPA, and are presented as the mean of three to four 
independent experiments. 
[3H]NMS binding (>94% of control) or agonist-stim- 
ulated PPI hydrolysis (>95% of control). To further 
characterize the TPA-induced diminution of musca- 
rinic receptor density and of 3H-inositol phosphate 
generation, all subsequent experiments were performed 
with a standard 5-day, 50-nM TPA pretreatment pe- 
riod. 
Scatchard analysis of [3H]NMS binding in untreated 
cells revealed a B,,, of 345 f 29 fmol/mg of protein 
(n = 4), with a corresponding KD value of 0.82 * 0.09 
nM (Fig. 5) .  However, cells treated for 5 days with 50 
nMTPA exhibited a significant 27% decline in the B,, 
of [3H]NMS binding ( p  < 0.05) without a significant 
change in the KD for the ligand. Saturation isotherms 
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FIG. 5. The effect of long-term TPA treatment on the binding 
properties of [3H]NMS. Intact SH-SYSY cells were incubated with 
increasing concentrations of [3H]NMS for 120 min at 37°C. Non- 
specific binding was obtained in the presence of 50 ~ J U  atropine. 
All data points were determined in duplicate, and results from one 
of four similar experiments are shown. 
KD values of 252 f 36 fmol/mg of protein and 0.83 
f 0.09 nM, respectively (Fig. 5).  Similarly, when 
[3H]scopolamine was utilized as the radioligand, a 27% 
reduction in B,, with no change in K D ,  was observed 
following TPA treatment (data not shown). 
To determine whether the inhibition of muscarinic 
receptor-mediated hydrolysis of inositol lipids was a 
result of a decrement in the maximal response and/or 
a change in agonist potency, we examined the ability 
of increasing concentrations of carbamylcholine to 
generate 3H-inositol phosphates in untreated and TPA- 
treated cells. The results demonstrate that TPA pre- 
treatment reduces the extent of agonist-stimulated 
inositol phosphate release by decreasing the maximal 
response without changing the ECS0 value (Fig. 6). Basal 
3H-inositol phosphate release was unaffected by prior 
treatment of SH-SY5Y cells with TPA. 
Muscarinic receptor density and stimulated PPI 
hydrolysis in SH-SYSY cells grown in 
serum-free media 
To determine whether differentiation of SH-SY5Y 
cells invariably leads to alterations in muscarinic re- 
ceptor signal transduction events, differentiation also 
was induced by removal of fetal calf serum from the 
medium. A small, although not significant ( p  > 0.05), 
increase in specific [3H]NMS binding (1 30 f 20% of 
control, n = 3) was observed in SH-SYSY cells grown 
for 6-7 days in serum-free media. Similarly, carba- 
mylcholine-stimulated 3H-inositol phosphate produc- 
tion increased to 136 & 16% of control (n = 3). How- 
ever, a greater incorporation of rny~-[~H]inositol into 
the inositol lipid pool in cells grown without serum 
( 1  56 f 4% of control) may account for much of this 
increase in inositol phosphate release. These results 
suggest that the differentiation of SH-SY5Y cells is not 
0 TPA-treated 
10 
-Log CCh Concentration. 0.4) 
FIG. 6. Dose-response curves of carbamylcholine (CCh)-stimu- 
lated accumulation of 3H-inositol phosphates in untreated and TPA- 
treated SH-SY5Y cells. Intact human neuroblastoma cells were 
treated with or without 50 nM 1PA for 5 days and incubated with 
CCh at the indicated concentrations. TPA treatment did not alter 
basal 3H-inositol phosphate release. Values shown are means for 
triplicate samples obtained from a single experiment. ECSo values 
for CCh (calculated by log-probit analysis) were 60 and 62 phf for 
untreated and TPA-treated cells, respectively. 
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necessarily accompanied by changes in muscarinic re- 
ceptor-effector coupling. 
Comparison of the effects of phorbol esters and 
mezerein on muscarinic receptor number and 
stimulated PPI hydrolysis 
It was consistently noted that TPA produced a 
greater reduction in carbamylcholine-stimulated 3H- 
inositol phosphate generation than in muscarinic re- 
ceptor density, whereas the biologically inactive 4a- 
PDD was without effect on both of these parameters 
(Table 1). On the other hand, mezerein was able to 
mimic the effects produced by TPA and elicited a 26 
and 53% inhibition of specific [3H]NMS binding and 
3H-inositol phosphate generation, respectively (Table 
1). Neither TPA nor mezerein pretreatment influenced 
the incorporation of myo-[3H]inositol into the inositol 
lipid pool under basal (no agonist) conditions [98 f 6% 
(n = 6) and 104 k 8% (n = 4) of control for TPA and 
mezerein, respectively]. When SH-SYSY cells were 
cultured in the presence of both TPA and mezerein, 
less than additive effects resulted (data not shown). 
Thus, these agents appear to mediatc their effects 
through a similar pathway or mechanism. 
Changes in [Ca2+ji n SH-SYSY cells following 
treatment with TPA or mezerein 
The fluorescent indicator, fura-2, was utilized to 
monitor both basal and agonist-stimulated [Ca"], val- 
ues in human neuroblastoma cells. Under resting con- 
ditions, a basal [Ca"], value of 39 f 4 nM (n = 13) 
was obtained in untreated SH-SYSY cells. Upon ag- 
onist addition, a rapid rise of [Ca"], to a value of 350 
f 24 nM(n = 13) was observed (Fig. 7A). This increase 
was transient and was followed by a decline to a plateau 
phase of the [Ca2'li signal (Fig. 7A; see Fisher et al., 
1989). Subsequent addition of atropine reduced the 
plateau Ca2+ value to that of basal [Ca2'], (Fig. 7A). 
TABLE 1. Efect ofphorbol eslers and mezerein on 
muscarinic receptor number and on miwarinic 
receptor-mediated generation of inositol phosphates 
TO control 
Specific Agonist-stimulated 
['HINMS 3H-IP generation 
Treatment binding (n) ( 4  
TPA, 50 nM 
~cx-PDD, 1,000 nM 
Mezerein, 100 nM 
72 t 3" (7) 
99 f 8 (3) 
74 ? 6" (4) 
SH-SYSY cells were treated for 5 days and values for ['HINMS 
binding and 'H-inositol phosphate (3H-IP) generation are expressed 
relative to control cells, which were treated identically except for 
absence of drug treatment. Cells were incubated with 5 n M  ['HINMS 
with or without 50 pM atropine for 120 min at 37°C. Generation of 
total 'H-IP was determined in the presence of 10 mM carbamylcho- 
line. Values represent the means k SEM for the number (n) of separate 
experiments indicated. 
52 k 4" (6) 
103 f 4 (4) 
47 f 8" (4) 
Significantly different from control, p i 0.05. 
I 
CCh Atr 
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FIG. 7. Effect of TPA and mezerein on the agonist-induced rise 
in [Ca2+]i in SH-SY5Y cells. Intact cells were loaded with 2 pM 
fura-P/AM for 15 rnin at 37°C. Cells were exposed to 10 rnM car- 
bamylcholine (CCh) and 10 phi atropine (Atr) at the times indicated. 
Representative traces are shown for untreated cells (A) and cells 
treated for 5 days with 50 nM TPA (B) or 100 nM mezerein (C). 
TPA and mezerein pretreatment had no effect on rest- 
ing [Ca"],. Thus, basal [Ca2+], values of 40 & 4 nM 
(n = 9) and 44 k 3 nM (n = 10) were obtained for 
TPA- and mezerein-treated SH-SYSY cells, respec- 
tively. However, a significant reduction (5 1-53%) in 
the magnitude of the initial rise in [Ca2+], was noted 
following chronic exposure of cells to these agents (Fig. 
7B and C). The peak [Ca2'], achieved following addi- 
tion of carbamylcholine to TPA-treated cells was 193 
k 9 nM (n = 9), whereas that for cells treated with 
mezerein was 19 1 k 16 nM (n = 10). A similar decline 
in agonist-stimulated [Ca2+], values was obtained in 
TPA- and mezerein-treated cells when muscarine was 
utilized as the agonist (data not shown). 
Pretreatment of SH-SYSY cells with TPA or 
mezerein depletes total PKC activity 
Chronic exposure of cells to phorbol esters has been 
reported to induce the down-regulation of PKC activ- 
ity. To determine the effects of long-term treatment 
with TPA and mezerein on levels of PKC, the activity 
of this enzyme was measured in both cytosol and 
membrane fractions obtained from SH-SYSY cells 
treated for 5 days with these agents. In untreated cells, 
70% of total PKC activity was associated with the cy- 
tosolic fraction, with the remainder localized to the 
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membrane (Table 2). A decrease in the amount of total 
PKC activity was apparent after treatment with 50 I1M 
TPA for 5 days, with levels of the enzyme reaching 
only 16% of control (Table 2). Pretreatment with 100 
nM mezerein also led to a similar depletion of PKC 
activity (Table 2). 
TPA and mezerein treatments inhibit NaF- and 
GTPyS-stimulated inositol phosphate production 
Because the loss of muscarinic receptors could not 
fully account for the decrement observed in stimulated 
PPI hydrolysis, we investigated the possibility that TPA 
and mezerein were inhibiting inositol phosphate gen- 
eration at an additional site distal to the receptor. Intact 
SH-SY 5Y cells were prelabeled for 24 h and then chal- 
lenged with NaF, a compound capable of stimulating 
the accumulation of inositol phosphates via direct in- 
teraction with G,. Table 3 shows that prior treatment 
of human neuroblastoma cells with TPA or mezerein 
significantly impaired the ability of NaF to induce 3H- 
inositol phosphate generation when compared with 
untreated cells. Under these conditions, carbamylcho- 
line-stimulated 3H-inositol phosphate formation was 
reduced to the same extent as that reported using the 
acute labeling paradigm (Tables 1 and 3). 
The site of TPA- and mezerein-induced inhibition 
of PPI hydrolysis was investigated further utilizing dig- 
itonin-permeabilized cells stimulated with GTPyS, a 
nonhydrolyzable analog of GTP. Addition of either 
GTPyS or carbamylcholine led to an increase in 3H- 
inositol phosphate generation in untreated cells, 
whereas a combination of both agents resulted in a 
synergistic accumulation (Fig. 8). Inclusion of 3 mM 
guanosine 5’-0-(2-thiodiphosphate) (GDPPS) substan- 
tially (40-70%) reduced carbamylcholine-stimulated 
and carbamylcholine plus GTPyS-stimulated 3H-ino- 
sitol phosphate release from permeabilized cells. Fur- 
thermore, inclusion of 20 pM atropine attenuated 
stimulated PPI turnover observed in the presence of 
TABLE 2. PKC activity in cytosol and membrane 
fractions of untreated, TPA-treated, and 
mezerein-treated SH-SYS Y cells 
PKC activity 
Cytosol Membrane 
pmol/min/mg % pmol/min/mg % 
of protein control of protein control 
Untreated 54.3 27.4 
TPA 8.5 15.7 4.5 16.4 
Mezerein 9.8 18.2 3. I 11.3 
Intact SH-SY5Y cells were pretreated with the designated agents 
for 5 days. Homogenates were prepared and PKC activity (phospha- 
tidylserine + diolein-induced 32P phosphorylation of histone 111-S) 
was determined in cytosolic and membrane fractions as described in 
Materials and Methods. Data are the average from two independent 
experiments, which differed by <10%. 
TABLE 3. Pretreatment with TPA and mezerein reduces 
the ability offluoride to stimulate ’H-inositol phosphate 
production in human SH-SYS Y neuroblastoma cells 
3H-Inositol phosphates produced 
(% control) 
Fluoride Carbamylcholine 
TPA 60.3 7.7 51.7 f 3.3 
Mezerein 55.8 * 2.8 42.9 f 2.7 
Intact SH-SY5Y cells were treated with or without 50 nM TPA 
or 100 nA4 mezerein for 5 days and prelabeled with rny~-[~H]inositol 
(5 pCi/ml) for the last day of this treatment. Intact, prelabeled cells 
(-500 jtg of protein) were incubated with 30 m/M NaF or 10 mM 
carbamylcholine for 20 min at 37°C. Results represent the means 
from four independent experiments. In pretreated cells, 3H-inositol 
phosphate release in basal and i n  fluoride- and carbamylcholine- 
stimulated incubations were 1,277 f 334, 3,790 & 610, and 22,962 
k 4,033 dpm/mg of protein, respectively. In untreated cells, a com- 
bination of fluoride and carbamylcholine resulted in accumulation 
of 3H-inositol phosphate generation greater than that observed with 
fluoride alone, but less than the maximal stimulation noted in the 
presence of agonist alone. 
carbamylcholine plus GTPyS to the level obtained for 
GTPyS alone, as previously observed for the SK-N- 
SH cell line (Fisher et al., 1989). The ability of carba- 
mylcholine to increase 3H-inositol phosphate release 
was reduced in TPA- and mezerein-treated SH-SY5Y 
cells to about 30% of control values (Fig. 8). GTPyS- 
stimulated 3H-inositol phosphate release was decreased 
to 7 1 and 66% of control in cells treated with TPA and 




G T M  CCh+GTPrS CCh 
FIG. 8. Effect of TPA and mezerein pretreatment on carbamyl- 
choline (CCh)- and GTPrS-induced inositol phosphate release in 
permeabilized SH-SY5Y cells. I-luman neuroblastoma cells were 
treated with or without 50 nM TPA or 100 OM mezerein for 5 days. 
[3H]lnositol-prelabeled cells were permeabilized with digitonin at a 
protein concentration of -4 mg/ml. Cells were then incubated 
witheither50pMGTPyS, 10mMCCh,orbothfor15minat37°C. 
A combination of CCh and GTPyS elicited a significant synergistic 
effect (p  < 0.05) in three of four experiments performed in untreated 
permeabilized cells and in all experiments in permeabilized cells 
from both TPA- and mezerein-treated groups. The Ca2+ concen- 
tration was maintained at 60 nM (Fisher et al., 1989). lnositol lipid 
labeling and basal ’H-inositol phosphate release remained unaf- 
fected by pretreatment with TPA or mezerein. Results shown are 
the means from three to four separate experiments. *Significantly 
different from untreated cells @ < 0.05). 
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carbamylcholine and GTPyS still elicited a synergistic 
effect in permeabilized cells obtained from both treated 
groups, the maximal stimulation was reduced to 70% 
when compared with untreated cells. Basal release of 
3H-inositol phosphates was not appreciably altered in 
treated cells. Direct activation of phospholipase C ac- 
tivity by the addition of 2 mM CaC12 to digitonin-per- 
meabilized cells resulted in a five- to sevenfold increase 
in 3H-inositol phosphate release over basal levels. This 
ability of Ca2+ to activate the enzyme directly was not 
impaired in cells pretreated with either TPA or meze- 
rein for 5 days (88-102% of control, n = 2). Taken 
together, the results suggest that treatments with TPA 
and mezerein inhibit not only muscarinic agonist-in- 
duced 3H-inositol phosphate formation but also that 
resulting from direct activation of G,. 
DISCUSSION 
The principal conclusion to emerge from the present 
study is that although long-term treatment of human 
neuroblastoma SH-SY5Y cells with TPA or mezerein 
results in a loss of muscarinic receptor number, a more 
pronounced reduction is observed for two biochemical 
consequences of receptor activation, namely agonist- 
stimulated PPI hydrolysis and Ca2+ signaling. Evidence 
obtained from both intact and permeabilized cells in- 
dicates that an additional site of action of these tumor 
promoters, at the level of G,-stimulated PPI hydrolysis, 
may account for their marked inhibitory effects on 
inositol lipid signaling events. 
In agreement with previous reports (Adem et al., 
1987; Heikkila et al., 1987), chronic treatment of SH- 
SYSY cells with TPA resulted in a loss of muscarinic 
receptor binding sites, reaching a maximal steady state 
after 5 days of treatment (Fig. 4 and Table I ) .  Com- 
parable losses of both ['H]scopolamine and [3H]NMS 
binding indicate that both cell surface and sequestered 
muscarinic receptors are equally down-regulated fol- 
lowing chronic TPA treatment (Fig. 4). Acute exposure 
of intact, confluent SH-SYSY cells with 50 nM TPA 
did not alter muscarinic receptor density. In contrast, 
a loss of muscarinic receptors has been reported for 
other cell lines following acute exposure to a similar 
concentration of TPA (Liles et al., 1986; Pearce et al., 
1988). 
Although muscarinic receptor density was reduced 
following chronic TPA and mezerein treatment, a 
consistently larger attenuation of agonist-induced PPI 
hydrolysis was observed (Table 1). This effect is due to 
a decreased maximal response without a change in the 
potency of the agonist for the receptor (Fig. 6). Utilizing 
intact and digitonin-permeabilized SH-SYSY cells, we 
obtained evidence that TPA and mezerein induce ad- 
ditional inhibitory effects on PPI hydrolysis at a site 
distal to the receptor. Pretreatment of cells with TPA 
or mezerein significantly reduced the ability of fluoride, 
an agent that causes activation of Gp through its dis- 
sociation, to stimulate PPI hydrolysis (Table 3). Sim- 
ilarly, the ability of GTPyS to enhance inositol phos- 
phate release from digitonin-permeabilized cells also 
was diminished following pretreatment with these 
agents (Fig. 8). TPA and mezerein did not affect the 
basal incorporation of myo-['H]inositol into the ino- 
sitol lipid pool, suggesting that substrate depletion 
probably does not account for the TPA- and mezerein- 
induced reduction in PPI hydrolysis. Thus, the present 
results are consistent with the possibility that in SH- 
SY5Y cells, treatment with either tumor promoter re- 
sults in inhibition of stimulated PPI hydrolysis at a site 
either at or distal to G,. Although inhibition of recep- 
tor-stimulated PPI hydrolysis following acute exposure 
of tissues to relatively high concentrations of phorbol 
esters is well documented (see Snider et al., 1987 and 
references therein), the underlying mechanism remains 
uncertain. In this context, inhibition of the G protein 
interaction with phospholipase C following acute TPA 
treatment has been demonstrated previously for 
132 1 N 1 human astrocytoma cells (Orellana et al., 
1987) and HL60 cells (Cockcrofi and Stutchfield, 1988; 
Geny et al., 1989), but not for primary astrocyte cul- 
tures (Pearce et al., 1988). Thus, the mechanism of 
TPA-induced inhibition of stimulated PPI hydrolysis 
may be tissue-specific. 
Pretreatment of SH-SYSY cells with TPA or meze- 
rein also resulted in a reduction in the carbamylcholine- 
stimulated rise in [Ca"], to an extent similar to that 
observed for stimulated PPI hydrolysis (-50%). In 
contrast, no effect of the tumor promoters on basal 
[Ca2'], was observed. These results indicate that the 
magnitude of the rise in [Ca2+], is proportional to the 
extent of PPI hydrolysis and suggest that these two 
events are closely coupled in SH-SY5Y cells, as pre- 
viously noted for SK-N-SH neuroblastoma cells (Fisher 
et al., 1989). 
In the SH-SYSY neuronal cell line, mezerein elicited 
morphological and biochemical changes similar to 
those induced by TPA (Table I), suggesting that these 
two agents function through a similar pathway or 
mechanism. Despite the fact that mezerein does not 
contain a diacylglycerol-like molecule in its structure, 
the compound is capable of activating PKC both in 
vitro and in vivo in a manner analogous to TPA (Mi- 
yake et al., 1984). In our study, long-term exposure to 
TPA or mezerein led to a marked depletion of total 
PKC activity in SH-SY5Y cells (Table 2). These results 
are consistent with the occurrence of down-regulation 
of PKC activity upon chronic exposure to phorbol es- 
ters, as observed for other cultured cell lines (Ballester 
and Rosen, 1985; Blackshear et al., 1985; Hepler et al., 
1988). Conversely, 4a-PDD, which does not activate 
PKC, did not reduce either specific ['HINMS binding 
or stimulated PPI hydrolysis (Table l), providing fur- 
ther evidence that activation of PKC is involved, at 
least in part, in the long-term effects of biologically 
active tumor promoters. Inhibition of guanine nucleo- 
tide-stimulated PPI hydrolysis in SH-SYSY cells fol- 
lowing TPA or mezerein treatment may reflect PKC- 
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mediated phosphorylation of G,, as previously pro- 
posed to occur in 132 1Nl astrocytoma cells (Orellana 
et al., 1987). TPA treatment of platelets results in the 
PKC-induced phosphorylation of the inhibitory gua- 
nine nucleotide regulatory protein Gi (Katada et al., 
1985). Alternatively, PKC may directly phosphorylate 
phospholipase C itself (Rhee et al., 1989). However, 
this possibility appears less likely in SH-SYSY cells as 
basal 3H-inositol phosphate release was unaffected by 
pretreatment with either TPA or mezerein. Moreover, 
the ability of a high concentration of calcium to activate 
phospholipase C directly and stimulate 3H-inositol 
phosphate release from digitonin-permeabilized SH- 
SYSY cells remained unchanged following chronic 
TPA or mezerein treatment, thus further reducing the 
likelihood of an inhibitory effect of the tumor pro- 
moters on phospholipase C itself. 
Whereas morphological differentiation of SH-SYSY 
cells resulted from pretreatment with TPA or mezerein, 
or removal of fetal calf serum, alterations in receptor 
number and in stimulated PPI turnover were observed 
only following pretreatment of the cells with the tumor 
promoters. These results suggest that differentiation of 
SH-SYSY cells is not necessarily accompanied by 
changes in signal transduction events, and that the in- 
hibitory effects of TPA and mezerein are likely to result 
from the direct activation of PKC and/or its subsequent 
down-regulation. 
In summary, long-term exposure to TPA or meze- 
rein resulted in a decline in muscarinic receptor-me- 
diated PPI hydrolysis with a concomitant decrease in 
agonist-induced Ca2+ mobilization and PKC activity 
in human neuroblastoma SH-SYSY cells. Our results 
indicate that the inhibitory effects produced by these 
agents are a consequence of a reduction in muscarinic 
receptor number as well as inhibition of G,-stimulated 
PPI hydrolysis. 
Acknowledgment: T h e  authors wish to thank Dr. Anne 
Heacock for performing the sodium dodecyl sulfate-urea gel 
electrophoresis. This work was supported by N I M H  Grant  
MH42652. C.L.C. is the recipient of a postdoctoral Training 
Grant, MH15794, from NIMH. 
REFERENCES 
Adem A., Mattsson M. E. K., Nordberg A,, and Pahlman S. (1987) 
Muscarinic receptors in human SH-SY5Y neuroblastoma cell 
line: regulation by phorbol ester and retinoic acid-induced dif- 
ferentiation. Dev. Brain Res. 33, 235-242. 
Akerman K. E. O., Scott I. G., and Anderson L. C. (1984) Functional 
differentiation of a human ganglion cell-derived neuroblastoma 
cell line SH-SY5Y induced by a phorbol ester (TPA). Neurochem. 
Int. 6, 77-80. 
Ballester R. and Rosen 0. M. (1985) Fate of imrnunoprecipitable 
protein kinase C in GH3 cells treated with phorbol 12-myristate 
13-acetate. J. Biol. Chem. 260, 15 194- I5 199. 
Biedler J. L., Roffler-Tarlov S., Schachner M., and Freedman L. S. 
(1978) Multiple neurotransmitter synthesis by human neuro- 
blastoma cell lines and clones. Cancer Res. 38, 375 1-3757. 
Blackshear P. J., Witters L. A., Girard P. R., Kuo J. F., and Quamo 
S. N. (1985) Growth factor-stimulated protein phosphorykdtion 
in 3T3-LI cells. J. Biol. Chem. 260, 13304-13315. 
Cheng Y.-C. and Pmsoff W. H. (1973) Relationship between the 
inhibition constant (KJ and the concentration of inhibitor which 
causes 50 percent inhibition (ICso) of an enzymatic reaction. 
Biochem. Pharmacol. 22, 3099-3 108. 
Cockcroft S. and Stutchfield J. (1988) Effect of pertussis toxin and 
neomycin on G protein-stimulated polyphosphoinositide phos- 
phodiesterase: a comparison between HL60 membranes and 
permeabilized cells. Biochem. J .  256, 343-350. 
Fisher S. K. (1988) Recognition of muscarinic cholinergic receptors 
in human SK-N-SH neuroblastoma cells by quaternary and ter- 
tiary ligands is dependent upon temperature, cell integrity, and 
the presence of agonists. Mol. Pharmacol. 33,4 14-422. 
Fisher S. K. and Bartus R. T. (1985) Regional differences in the 
coupling of muscarinic receptors to inositol phospholipid hy- 
drolysis in guinea pig brain. J.  Neurochem. 45, 1085-1095. 
Fisher S. K. and Heacock A. M. (1988) A putative M3 muscarinic 
cholinergic receptor of high molecular weight couples to pbos- 
phoinositide hydrolysis in human SK-N-SH cells. J. Neurochem. 
SO, 984-987. 
Fisher S. K. and Snider R. M. (1987) Differential receptor occupancy 
requirements for muscarinic cholinergic stimulation of inositol 
lipid hydrolysis in brain and in neuroblastomas. Mol. Pharmacol. 
32,81-90. 
Fisher S. K., Domask L. M., and Roland R. ( 1  989) Muscarink re- 
ceptor regulation of cytoplasmic Ca2+ concentrations in human 
SK-N-SH neuroblastoma cells: Ca2+ requirements for phospbo- 
lipasc C activation. Mol. Pharmacol. 35, 195-204. 
Fowler C. J., Oneill C., Almqvisl P., Nilsson S., Wiehagen B., and 
Winblad B. (1989) Muscarinic receptors coupled to inositol 
phospholipid breakdown in human SH-SY 5Y neuroblastoma 
cells: effect of retinoic acid-induced differentiation. Neurochem. 
Int. IS, 73-79. 
Geiger P. J. and Bessman S. P. (1972) Protein determination by Low- 
ry's method in the presence of sulfhydryl reagents. Anal. Biochem. 
Geny B., Stutchfield J., and Cockcroft S. (1989) Phorbol ester inhibits 
polyphosphoinositide phosphodiesterase activity stimulatcd by 
either Ca2+, fluoride, or GTP analogue in HL60 membranes and 
in permeabilized cells. CeN. Signal 1, 165-172. 
Grynkiewicz G., Poenie M., and Tsien R. Y. (1985) A new generation 
of Ca2+ indicators with greatly improved fluorescence properties. 
J. Biol. Chem. 260,3440-3450. 
Heikkila J. E., Scott 1. G., Suominen L. A,, and Akerman K. E. 0. 
(1987) Differentiation-associated decrease in muscarinic receptor 
sensitivity in human neuroblastoma cells. J. Cell. Physiot. 130, 
I 57- 162. 
Hepler J. R., Earp H. S., and Harden T. K. (1988) Long-term phorbol 
ester treatment down-regulates protein kinase C and sensitizes 
the phosphoinositide signaling pathway to hormone and growth 
factor stimulation. J. Bid.  C'hem. 263, 7610-7619. 
Honegger P. and Richelson E. (1 976) Biochemical differentiation of 
mechanically dissociated mammalian brain in aggregating cell 
culture. Brain Res. 109, 335-354. 
Katada T., Gilman A. G., Watanabe Y., Bauer S., and Jakobs K. H. 
(1985) Protein kinase C phosphorylates the inhibitory guanine 
nucleotide binding regulatory component and apparently sup- 
presses its function in hormonal inhibition of adenylate cyclase. 
Eur. J. Biochem. 151,431-437. 
Lambert D. G., Ghataorre A. S., and Nahorski S. R. (1989) Muscarinic 
receptor binding characteristics of a human neuroblastoma SK- 
N-SH and its clones SH-SY5Y and SH-EPl . Eur. J. Pharmacol. 
Liles W. C., Hunter D. D., Meier K. E., and Nathanson N. W. ( 1  986) 
Activation of protein kinase C induces rapid internalization and 
subsequent degradation of muscarinic acetylcholine receptors 
in neuroblastoma cells. J. Biol. Chem. 261, 5307-53 13. 
Miyake R., Tanaka Y., Tsuda T., Kaibuchi K., Kikkawa U., and 
Nishizuka Y. (1984) Activation of protein kinase C by non- 




J.  Nrurochrm.. Vol. 54, No. 5. 1990 
1734 C. L. CIOFFI AND S. K. FISHER 
Munson P. J. and Rodbard D. (1980) LIGAND: a versatile com- 
puterized approach for characterization of ligand-binding sys- 
tems. Anal. Biochern. 107, 220-239. 
Nishizuka Y. (1984) The role of protein kinase C in cell surface signal 
transduction and tumour promotion. Nature 308, 693-698. 
Orellana S., Solski P. A., and Brown J. 13. (1987) Guanosine 5’-0- 
(thiotnph0sphate)-dependent inositol tnphosphate formation in 
membranes is inhibited by phorbol ester and protein kmase C.  
J. Biol. Chem. 262, 1638-1643. 
Pahlman S., Odelstad L., Larsson E., Grotte G., and Nilsson K. (198 1) 
Phenotypic changes of human neuroblastoma cells in culture 
induced by 12-0-tetradecanoylphorbol 13-acetate. Znt. J. Cancer 
Pahlman S., Ruusala A.-I., Abrahamsson L., Mattsson M. E. K., and 
Esscher T. (1984) Retinoic acid-induced differentiation of cul- 
tured human neuroblastoma cells: a comparison with phorbol 
ester-induced differentiation. Cell D/fler. 14, 135- 144. 
Pearce B., Morrow C., and Murphy S. (1988) Characteristics ofphor- 
28,583-589. 
bol ester- and agonist-induced down-regulation of astrocyte re- 
ceptors coupled to inositol phospholipid metabolism. J. Neu- 
rochem. 50,936-944. 
Rhee S. G., Suh P.-G., Ryu S.-H., and Lee S. Y. (1989) Stumes of 
inositol phospholipid-specific phospholipase C. Science 244,546- 
550. 
Scatchard G. (1949) The attractions of proteins for small molecules 
and ions. Ann. NY Acad. Sci. 51, 660-672. 
Serra M., Mei L., Roeske W. R., Lui G. K., Watson M., and Ya- 
mamura H. I. (1988) The intact neuroblastoma cell (SH-SYSY) 
exhibits high-affinity [3H]pirenzepine binding associated with 
hydrolysis o f  phosphatidylinositols. J. Neurochem. 50, 15 13- 
1521. 
Snider R. M., Fisher S. K., and Agranoff B. W. (1987) Inositide- 
linked second messengers in the central nervous system, in Psy- 
chopharmncolrigy: The Third Generation of Progress (Meltzer 
H. Y., ed), pp. 317-324. Raven Press, New York. 
J. Neurochem.. Vol. 54, NO. 5. 1990 
